Advanced Catheter Therapies and Toray in deal for Occlusion catheter


Advanced Catheter Therapies ($ACT), the maker of a localized drug delivery system for the peripheral vasculature, is teaming with Toray Industries ($TORAY) to manufacture, market and sell ACT’s FDA-cleared Occlusion Perfusion Catheter (OPC).

The drug delivery device is a targeted therapeutic agent system designed exclusively for the field of peripheral vascular stenosis and restenosis. The company began manufacturing the OPC last year for use in supporting clinical trials and for a targeted test market release.

“Our first-in-human clinical trials have been very encouraging, and we have successfully met our milestones for safety and efficacy,” Paul Fitzpatrick, chief executive of ACT, said in a statement. 

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

The company forecasts the global market for the treatment of peripheral arterial disease and targeted drug delivery to reach $3 billion by 2020. Terms of the global agreement were not disclosed.

The OPC received 510(k) clearance in October 2013. The single-use device creates a localized treatment chamber that prevents systemic release of various drugs selected by the physician. It contains 5 lumens and has a fiber-optic pressure sensor to monitor pressure within the treatment chamber and enable real-time adjustments.

After the catheter is placed in the correct part of the vessel via a guidewire, the balloon lumens at each end of the catheter inflate to form a treatment chamber, according to a company video. Then, the blood is evacuated from the treatment chamber using a saline solution. Next, the drug is delivered from within the catheter. Finally, the balloons are deflated and the catheter is removed from the body.

- here’s the release
- read more here


Suggested Articles

With a slate of vaccine authorizations on the horizon, vaccine execs from a trio of leading shot makers are looking at distribution hurdles ahead.

News of an FDA plant inspection for a Macrogenics drug boosted investor confidence in BMS' ability to meet its year-end deadline for liso-cel.

BioCryst has scored FDA approval for Orladeyo, the first oral option to prevent hereditary angioedema attacks in patients 12 and older.